Skip to main content
ABOUT US

Empowering scientists to develop better medicines through deeper understanding of disease biology.

About Bifrost

Two kinds of systems biology have had a big impact on health. One provides great depth in terms of dynamics and spatial organization by directly observing live cells under the microscope. The other achieves great breadth through genome-scale perturbations and measurements.

Bifrost bridges the two, and also pushes the limits of both – imaging pooled libraries of hundreds of millions of cells with super-resolution and then genotyping each one.”

– Johan Paulsson, PhD
    Scientific Founder

Our Story

Bifrost (biv-rost)

Noun. Norse Mythology.

The rainbow bridge of the gods
from Asgard, their home
to Midgard, the earth.

 

 

 

Adapting this concept to cell biology, Bifrost Biosystems aims to power efficient discoveries by optically linking deep, multiparameter single-cell phenotypes to related genes – an optical bridge to better understanding of biology.

How it began

Bifrost is a 2021 spinout from the Paulsson Lab at Harvard Medical School as part of a Defense Advanced Research Projects Agency (DARPA)-sponsored program, the Embedded Entrepreneur Initiative (EEI), aimed at translating innovative technologies from academia. Additional optical pooled screening expertise from the Elf Lab at Uppsala University in Sweden, the Church Lab at HMS and the Blainey Lab at the Broad Institute of MIT/Harvard has strengthened the technological depth and know-how of Bifrost. In late 2023, Bifrost was named in a major Advanced Research Projects Agency for Health (ARPA-H) program grant as the subcontractor responsible for delivering the core optical pooled screening instrumentation for the larger program.

Today, Bifrost continues its mission to democratize access to optical-pooled-screening technology as the tool for unlocking previously inaccessible understanding of complex biological pathways and processes.

Our team

Founders

The Bifrost team of industry leading-experts is dedicated to deciphering connections at the cellular level that propel novel biological discoveries.

Johan Paulsson, PhD

A leading researcher in single-cell dynamics, especially in method development and mathematical theory for stochastic processes.

Read Full Bio

Paul Blainey, PhD

Pioneering the integration of molecular, optical, microfluidic and computational technologies to solve pressing unmet research and medical needs.

Read Full Bio

Shawn Marcell

A 30-year veteran with expertise leading interdisciplinary teams in technology and the life sciences.

Read Full Bio

George Church, PhD

Geneticist, molecular engineer, chemist, serial entrepreneur and pioneer in personal genomics and synthetic biology.

Read Full Bio

Johan Elf, PhD

A creative inventor of experimental methods and computational tools to study life at the molecular level

Read Full Bio

Leadership Team

Jonas Jarvius, PhD

Transformational life sciences leader with a proven track record of translating technologies into health solutions.

Read Full Bio

Keith Breinlinger, PhD

Engineer, inventor and experienced executive leading high-functioning multidisciplinary teams.

Read Full Bio

Jackie Lemaitre, MBA

Corporate strategist with successful track record launching new entities and commercializing novel therapies, diagnostics and tools.

Read Full Bio

Greg Kellogg, PhD

Scientist, engineer and executive with a passion for the intersection of fluidics, microfabrication and biology.

Read Full Bio
Johan Paulsson

Johan Paulsson, PhD


A leading researcher in single-cell dynamics, especially in method development and mathematical theory for stochastic processes.
Johan Paulsson is a Professor of Systems Biology at Harvard University. His lab works on dynamic processes in single cells, combining mathematical theory for stochastic processes, microfluidics, microscopy and new biochemical assays. Dr. Paulsson earned his PhD from Uppsala University, Sweden, on theory for stochastic chemistry, and was a Lewis-Thomas Fellow at Princeton University before becoming a tenured faculty member in the Department of Applied Mathematics and Theoretical Physics at the University of Cambridge. He joined Harvard in 2005, where he also serves as the founding faculty Director for the HMS microfabrication facility and for Theory in Biology.
Paul Blainey

Paul Blainey, PhD


Pioneering the integration of molecular, optical, microfluidic and computational technologies to solve pressing unmet research and medical needs
Paul Blainey is a core member of the Broad Institute of MIT and Harvard and an associate professor in the Department of Biological Engineering at MIT. An expert in microanalysis systems for studies of individual molecules and cells, his group develops and translates microfluidic, imaging, genomic, and computational approaches to create and share scalable solutions to major challenges in the life sciences and biomedicine. Dr. Blainey holds a BS in chemistry and BA in mathematics from the University of Washington, Seattle. He earned a PhD in physical chemistry from Harvard University and completed postdoctoral research at Stanford University.
Johan Elf

Johan Elf, PhD


A creative inventor of experimental methods and computational tools to study life at the molecular level
Johan Elf is a professor of physical biology at the Department of Cell and Molecular Biology at Uppsala University. A pioneer in single-molecule kinetics investigations in living bacterial cells, Elf is known for his creativity in inventing new experimental methods and computational tools to study life at the molecular level. The Elf group works across the boundaries of the traditional scientific disciplines to address fundamental biological questions related to gene expression, chromosome structure, and the bacterial cell cycle. Dr. Elf earned his Ph.D. in Molecular Biotechnology from Uppsala University, where he studied the theoretical aspects of metabolic fluxes in E. coli with Måns Ehrenberg. He then completed postdoctoral research at Harvard in the laboratory of Sunny Xie, where he pioneered the use of single-molecule fluorescence microscopy to measure in vivo kinetics. Since 2016, Elf has been a member of the Swedish Royal Academy of Sciences, where he also serves on the board. He is the recipient of several prestigious research awards, including the Gustafsson Prize in 2010 and the Norblad-Ekstrand medal in 2021.
George Church

George Church, PhD


Geneticist, molecular engineer, chemist, serial entrepreneur and pioneer in personal genomics and synthetic biology
George Church is Professor of Genetics and Director of PersonalGenomes.org, which provides the world’s only open-access information on human Genomic, Environmental & Trait data (GET). His 1984 Harvard PhD included the first methods for direct genome sequencing, molecular multiplexing & barcoding. These led to the first genome sequence (pathogen, Helicobacter pylori) in 1994. His innovations have contributed to nearly all “next generation” DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Nanopore). This plus his lab’s work on chip-DNA-synthesis, gene editing and stem cell engineering resulted in founding additional application-based companies spanning fields of medical diagnostics (Knome/PierianDx, Alacris, Nebula, Veritas) & synthetic biology/therapeutics (AbVitro/Juno, Gen9/enEvolv/Zymergen/Warpdrive/Gingko, Editas, Egenesis). He has also pioneered new privacy, biosafety, ELSI, environmental & biosecurity policies. He was director of an IARPA BRAIN Project and 3 NIH Centers for Excellence in Genomic Science (2004-2020). His honors include election to NAS & NAE & Franklin Bower Laureate for Achievement in Science. He has coauthored 650 papers, 156 patent publications & a book (Regenesis).
Shawn Marcell

Shawn Marcell


A 30-year veteran with expertise leading interdisciplinary teams in technology and the life sciences
Shawn serves as the Executive Chairman and Principal Executive Officer and is a Co-founder of Bifrost Biosystems. He has nearly three decades of diverse executive, commercial, and operational experience in life science and technology businesses. Previously, while serving as Entrepreneur in Residence at the Wyss Institute, he co-founded and spun-out Torus Biosystems in 2020 and ReadCoor in 2016, serving as Chairman & CEO for both companies. ReadCoor was acquired in 2020 by 10X Genomics. Shawn has founded and chaired several other early-stage venture-backed life sciences companies including RedPoint Bio which went public in 2005, Sensigen which was acquired by Sequenom, Lifecodes division of Hologic acquired by Immucor/TPG, and Metamark Genetics acquired by LabCorp. Mr. Marcell earned a BA degree in Economics from The George Washington University.
Jonas Jarvius, PhD

Jonas Jarvius, PhD


A transformational life sciences leader with a proven track record of translating innovative technologies into health solutions.
Jonas serves as President, CEO and Director of Bifrost Biosystems. He brings over 15 years of C-level executive experience from both private and public companies translating innovative technologies into commercial products that impact human health outcomes. Dr. Jarvius earned his doctoral degree in Molecular Medicine from Uppsala University where his research focused on developing Proximity Ligation and Padlock probe-based molecular recognition technologies as well as isothermal amplification techniques. Several of these technologies have subsequently been commercialized in successful companies such as Olink, Q-linea, Umbrella Science, and Sigolis (Ginolis) where Jonas is a founder or cofounder. Dr. Jarvius most recently served as chief executive officer of Q-Linea, a diagnostics company focused on improving sepsis treatment and reducing antimicrobial resistance. In this role, he led the company from an initial technology to a multinational commercial enterprise.
Keith Breinlinger

Keith Breinlinger, PhD


Engineer, inventor and experienced executive leading high-functioning multidisciplinary teams
Keith Breinlinger holds the position of Chief Technology Officer (CTO) and General Manager of Bifrost Biosystems. Dr. Breinlinger brings more than a decade of experience leading high functioning multidisciplinary teams to drive R&D development programs from initial concept to commercialization, and he is a named inventor on more than 30 patents. Previously, Keith served as CTO of Berkeley Lights, now PhenomeX and acquired by Bruker in 2023, where he led the development team including biology, software, hardware, applications, chips, reagents, and program management. Prior to joining Berkeley Lights, Keith worked in the semiconductor equipment industry for 17 years at Teradyne and FormFactor. At Formfactor, he led the development of multiple platforms (Kepler and SmartMatrix) that are still in use today. Keith received his PhD, MS, and BS from MIT in Mechanical Engineering focused on Precision Machine Design, heat transfer, and MEMS.
Greg Kellogg, PhD

Greg Kellogg, PhD


Scientist, engineer and executive with a passion for the intersection of fluidics, microfabrication and biology
Greg Kellogg is the Director of R&D at Bifrost Biosystems, managing technical activities and serving as the Principal Investigator on federal grants and contracts. He brings more than 25 years of experience as a scientist/engineer, manager, and executive working at the intersection of fluidics, microfabrication, and biology to develop products and technologies for diagnostic and life science tools companies. Previously, Dr. Kellogg served as a leader on the technical teams at Gamera Bioscience (acquired by Tecan) and Network Biosystems (now ANDE) where he developed microfluidic systems and products. Most recently, he served as PI on several NIH and Massachusetts state grants while working at Covaris. He has also consulted for point-of-care and clinical diagnostics projects as well as in drug discovery. Dr. Kellogg, named inventor on numerous patents, holds a BS in Physics from Cornell University, and earned a PhD in Physics from Harvard University.
Jackie Lemaitre

Jackie Lemaitre, MBA


Corporate strategist with successful track record launching new entities and commercializing novel therapies, diagnostics and tools.
Jackie Lemaitre is a seasoned professional currently serving as the Vice President of Corporate Development at Bifrost Biosystems. She brings over a decade of life sciences experience focused on the commercialization of novel, innovative medical diagnostics, therapies, and research tools. Prior to joining Bifrost, Jackie served as VP of Market Development at Torus Biosystems, a pioneering diagnostics company specializing in solutions for infectious diseases. She has managed all aspects of product commercialization programs, as well as directed the product pipeline strategies for companies including Avedro (acquired by Glaukos), T2 Biosystems and QIAGEN. Jackie earned her MBA from McGill University and her BS in Biology from Boston College.